Drug Profile


Alternative Names: SMT-19969

Latest Information Update: 12 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Summit plc
  • Developer Summit Therapeutics
  • Class Antibacterials; Benzimidazoles; Pyridines; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Clostridium infections

Most Recent Events

  • 11 Sep 2017 Summit Therapeutics plans two phase III trials for Clostridium infections in June 2018
  • 11 Sep 2017 Summit Therapeutics receives grant from US BARDA for development of ridinilazole in Clostridium infections
  • 05 Sep 2017 Adverse event and efficacy data from the phase II CoDIFy 2 trial in Clostridium infections released by Summit Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top